骨髓间充质干细胞分化为胰岛细胞治疗糖尿病

Transdifferentiation of Bone Marrow Mesenchymal Stem Cells into Islet Cells to Treat Diabetes Mellitus

糖尿病已成为严重危害人类健康的疾病之一。目前,移植胰岛治疗糖尿病已初见疗效,但由于胰岛来源匮乏和免疫排斥反应而受阻。骨髓间充质干细胞(bonemarrowmesenchymalstemcells,BMMSCs)取材方便,容易进行体外分离、培养和纯化,且具有跨越分化潜能。若将自体BMMSCs诱导分化为胰岛细胞,可望解决细胞来源和免疫排除问题,实现糖尿病的自体细胞治疗。现对体外诱导BMMSCs分化为胰岛细胞治疗糖尿病的研究进展进行综述,并指出了存在问题和今后的研究方向。

Diabetes mellitus is a serious disease damaging human being＇s health. At present, the curative effect of transplantation of pancreatic islets used to treat diabetes mellitus appears. However, it is limited with the lack of pancreatic islets and immunological rejection. Bone marrow mesenchymal stem cells （BMMSCs）, easily separated, cultured and purified, have multi-differentiation potential. If BMMSCs are induced to transdifferentiate into islet cells, the problems of lacking pancreatic islets and immunological rejection can be entirely solved, and diabetes mellitus can be cured with patient＇s marrow cells. In this paper, the progress of transdifferentiation from BMMSCs into islet cells to treat diabetes mellitus was fully reviewed, and the problems and research directions were discussed.